Related Experiment Video
Updated: Jul 9, 2026
05:02
Mechanical Micronization of Lipoaspirates for Regenerative Therapy
Published on: March 15, 2019
Lispro insulin-induced lipoatrophy: a new case
Sultan Al-Khenaizan1, Mastour Al Thubaiti, Ibrahim Al Alwan
1Division of Dermatology, Department of Medicine, King Fahad National Guard Hospital, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia. khenaizans@ngha.med.sa
Pediatric Diabetes
|November 27, 2007
Summary
Lipoatrophy, a rare complication of insulin therapy in type 1 diabetes, may be caused by lispro insulin. This case report details a young girl experiencing lipoatrophy and reviews current understanding of this condition.
Area of Science:
- Endocrinology
- Immunology
- Pediatrics
Background:
- Lipoatrophy (LA) is an uncommon adverse effect associated with insulin therapy in patients with type 1 diabetes mellitus.
- The exact mechanisms underlying insulin-induced LA remain unclear, with immunological responses being a leading hypothesis.
Observation:
- This report presents a case of a 4-year-old Saudi girl who developed lipoatrophy.
- The lipoatrophy was potentially induced by lispro insulin, a rapid-acting insulin analog.
Findings:
- The case suggests a possible link between lispro insulin use and the development of lipoatrophy in a pediatric patient.
- A literature review was conducted to explore clinical features, pathophysiology, differential diagnoses, and treatment options for insulin-induced LA.
Implications:
- This case highlights the need for further research into the pathogenesis of insulin-induced lipoatrophy.
- Understanding the immunological basis may lead to improved prevention and management strategies for this rare complication in type 1 diabetes treatment.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:25Diabetic Ketoacidosis l: Introduction
DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...